by Raynovich Rod | Nov 25, 2015 | Biopharmaceuticals
Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants...
by Rod Raynovich | Feb 10, 2010 | BIOgraph
Clinical Profile concerns spur a big sell-off : ISIS shares down 14.6% to $9.40 on volume of 10.6M shares The Mipomersen Phase 3 study in patients with Heterozygous Familial Hypochesterolemia, a genetic disorder, met its primary endpoint but investors were worried...